Chord Therapeutics closes its USD 16 million Series A financing
On October 13, 2020, Chord Therapeutics, a Geneva clinical stage biopharmaceutical company developing drugs for rare diseases, announced the closing of a USD 16 million Series A financing from leading healthcare investor Omega Funds. The financing will allow the company to progress its lead drug candidate, CRD1, a small molecule oral drug for the treatment of neuromyelitis optica spectrum disorders (NMOSD), through Phase 2 proof of concept clinical development.
Lenz & Staehelin advised Chord Therapeutics in its Series A financing. The team was led by Guy Vermeil and included David Ledermann and Federico Trabaldo Togna (all Corporate, M&A), Floran Ponce (Tax), Sevan Antreasyan (Intellectual Property) and Prisca Cattaneo (Employment).